👨‍🔬

Stephen J. Nicholls

Professor

Monash University · Faculty of Medicine and Health Sciences

Opportunity Signal中

该方向可能存在研究机会，建议进一步了解

研究方向

Lipoproteins and Cardiovascular HealthCardiac Imaging and DiagnosticsCoronary Interventions and DiagnosticsDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and Metabolism

学术数据

106

H-Index

1316

论文

64911

引用

联系方式

📧stephen.nicholls@monash.edu 🔗大学主页

代表论文 via Semantic Scholar

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.↗

2025· Lancet· 引用 36

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials↗

2026· American Journal of Preventive Cardiology· 引用 1

†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results↗

2024· Journal of Clinical Lipidology· 引用 1

Zodasiran silences hepatic ANGPTL3 leading to deep and durable reductions in atherogenic lipids and lipoproteins in mixed dyslipidemia patients: Final results from arches-2, double-blind period↗

2024· Atherosclerosis· 引用 1

Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results↗

2024· Atherosclerosis

⚠️ 数据说明：本页信息来源于大学官网、Google Scholar 及公开数据库，仅供参考。教授的招生状态、经费情况和研究方向可能随时变化，具体信息请以导师本人确认为准。Koala PhD 不对信息的准确性和时效性承担责任。

v1.087